Ozempic Is About to Go Generic in India, China and Canada

In India, China and several other nations, Novo Nordisk is on the verge of losing patent protection for its blockbuster weight loss drug, opening the door for cheaper competing versions.

The New York Times
This will be huge. Companies like Hims and Ro charge thousands of dollars a month with drugs that don't have the patents expire. I'm hopeful this will expand the ability to receive treatment and also allow trials to be tested at greater length to understand long-term effects.